A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.

被引:16
作者
Gounder, Mrinal M.
Bauer, Todd Michael
Schwartz, Gary K.
Masters, Tyler
Carvajal, Richard D.
Song, Saeheum
Kumar, Prasanna
Gajee, Roohi
Zernovak, Oleg
Rosen, Michael M.
Kochan, Jarema Peter
Chen, Shuquan
Hyman, David Michael
Gokmen, Sugun
Meric-Bernstam, Funda
LoRusso, Patricia
Somaiah, Neeta
Weise, Amy M.
Hong, David S.
机构
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Tennessee Oncol PLLC, Nashville, TN USA
[4] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA
[5] Columbia Univ, Med Ctr, New York, NY USA
[6] Daiichi Sankyo, Parsippany, NJ USA
[7] Daiichi Sankyo, Collegeville, PA USA
[8] Daiichi Sankyo Inc, Edison, NJ USA
[9] Daiichi Sankyo Pharma Dev, Teaneck, NJ USA
[10] Daiichi Sankyo Pharma Dev, Edison, NJ USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase 1 Program,Dept Surg Oncol, Sheikh Khalifa Bin Zayed Al Nahyan Inst Personali, Houston, TX 77030 USA
[12] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Karmanos Canc Inst, Troy, MI USA
[15] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase 1 Program, Houston, TX 77030 USA
关键词
D O I
10.1200/JCO.2016.34.15_suppl.2581
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2581
引用
收藏
页数:2
相关论文
empty
未找到相关数据